Abstract
Human mutations in keratin 8 (K8) and keratin 18 (K18), the intermediate filament proteins of hepatocytes, predispose to several liver diseases. K8-null mice develop chronic liver injury and fragile hepatocytes, dysfunctional mitochondria, and Th2-type colitis. We tested the hypothesis that autoantibody formation accompanies the liver damage that associates with K8/K18 absence. Sera from wild-type control, K8-null, and K18-null mice were analyzed by immunoblotting and immunofluorescence staining of cell and mouse tissue homogenates. Autoantibodies to several antigens were identified in 81% of K8-null male mice 8 mo or older. Similar autoantibodies were detected in aging K18-null male mice that had a related liver phenotype but normal colon compared with K8-null mice, suggesting that the autoantibodies are linked to liver rather than colonic disease. However, these autoantibodies were not observed in nontransgenic mice subjected to 4 chronic injury models. The autoantigens are ubiquitous and partition with mitochondria. Mass spectrometry and purified protein analysis identified, mitochondrial HMG-CoA synthase, aldehyde dehydrogenase, and catalase as the primary autoantigens, and glutamate dehydrogenase and epoxide hydrolase-2 as additional autoantigens. Therefore, absence of the hepatocyte keratins results in production of anti-mitochondrial autoantibodies (AMA) that recognize proteins involved in energy metabolism and oxidative stress, raising the possibility that AMA may be found in patients with keratin mutations that associate with liver and other diseases.—Toivola, D. M., Habtezion, A., Misiorek, J. O., Zhang, L., Nyström, J. H., Sharpe, O., Robinson, W. H., Kwan, R., Omary, M. B. Absence of keratin 8 or 18 promotes antimitochondrial autoantibody formation in aging male mice.
Keywords: autoimmune liver disease, GDH, HMGCS2, ALDH, intermediate filaments
Keratins make up the intermediate filament (IF) cytoskeleton of epithelial cells and include the obligate heteropolymeric keratin types I (keratins 9–28, 31–40) and II (keratins 1–8, keratins 71–80) (1). Simple-type epithelia, as found in the liver, pancreas, and intestine, express multiple keratins (keratins 7, 8, 18–20) (2, 3), but adult hepatocytes are unique because they express only keratin 8 (K8) and keratin 18 (K18) (3). The main function of keratins is to protect from cellular stress (4, 5) as supported by >80 human diseases that are caused or predisposed to by mutations in IF proteins (2, 6, 7). Human K8, K18 and K19 variants predispose to progression of several liver diseases including primary biliary cirrhosis (PBC) (8), hepatitis C virus infection (9), and acute liver failure (10). In contrast, the role of K8 mutations in inflammatory bowel disease (IBD) is less clear, likely due to functional redundancy of additional keratins (11). Multiple transgenic mouse models that lack keratins or express keratin mutants (3, 12) support the human disease relationship of K8/K18. For example, K8- or K18-null (K8−/−, K18−/−) mice develop spontaneous mild hepatitis (13–15) and are highly susceptible to apoptosis and toxin-mediated liver injury (16, 17). Both K8−/− and K18−/− mouse livers lack any K8 and K18 protein because the absence of one keratin causes proteosomal degradation of its partner keratin (18). Although the intestine appears normal in K18−/− mice (14), K8−/− mice develop a Th2-type ulcerative colitis, colorectal hyperproliferation, microflora-dependent decreased susceptibility to apoptosis, and mistargeting of subcellular proteins (13, 19–21). These intestinal manifestations are similarly observed in several IBD mouse models, including those lacking T-cell receptor-α (22) or IL-10 (23).
Patients with IBD or liver autoimmune diseases often produce serum autoantibodies that are used in diagnosis (24, 25). Common autoantibodies in the autoimmune liver diseases primary sclerosing cholangitis (PSC), PBC, and autoimmune hepatitis include anti-mitochondrial autoantibodies (AMA), anti-nuclear antibodies, smooth muscle antibody, or antibody to liver kidney microsome type-1 (25, 26). Patients with IBD may also harbor serum antibodies including perinuclear anti-neutrophil cytoplasmic antibodies (in ulcerative colitis) and anti-Saccharomyces cerevisiae antibodies (in Crohn’s disease) (24). The phenotypes of K8−/− mice that involve the colon and liver, coupled with the association of K8 variants with PBC (8), prompted us to hypothesize that autoantibody formation accompanies the liver damage associated with K8 or K18 absence in K8−/− and K18−/− mice. We validated this hypothesis by showing that aging male mice develop AMA, and we identified some of the autoantigen components recognized by these antibodies.
MATERIALS AND METHODS
Animal experiments and cells
K8−/−, K8+/−, wild-type K8+/+ (13), and K18−/− mice were bred and genotyped as described elsewhere (13, 14). Mice that overexpress wild-type human K18 and mutant Arg90Cys human K18 (K18 R89C) (27) were also used. Mice received humane care, and their use was performed in accordance with the Committees on Use and Care of Animals. Tissue lysates generated from FVB/n mice were used for serum screening. Mice were also exposed to 4 different liver injury models, including: 1) a combined high-fat and high-carbohydrate diet that consists of a Surwit diet supplemented with fructose and sucrose (in the drinking water) for 14 wk as described elsewhere (28); 2) the established porphyrinogenic 3,5-diethoxycarbonyl-1,4-dihydrocollidine liver injury model in which mice were fed a powdered chow (Formulab Diet 5008, LabDiet, St. Louis, MO, USA) containing 0.1% diethoxycarbonyl dihydrocollidine (Sigma-Aldrich, St. Louis, MO, USA) for 3 mo (29); and the liver fibrosis models that involved administering 3) CCl4 for 8 wk or 4) thioacetamide for 6 wk (30). Sera were collected and used for autoantibody screening as described below. Cell lines (American Type Culture Collection, Manassas, VA, USA) used included human Huh7 hepatoma and HT29 colon carcinoma cells, mouse NIH-3T3 fibroblasts and pancreatic LTDA cells. Cells were cultured at 37°C in media as recommended by the supplier.
Antibodies
Primary antibodies used were rabbit anti-superoxide dismutase 2 (SOD-2), anti-prohibitin (Abcam, Cambridge, MA, USA); anti-gpp130; anti-Hsp70 (Enzo Life Sciences, Farmingdale, NY, USA); rabbit anti-vinculin (Sigma-Aldrich); anti-catalase and anti-PMP70 (Thermo Fisher Scientific, Waltham, MA, USA); anti-cytochrome c (Cell Signaling, Danvers, MA, USA); anti-K8 and anti-K19 (Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA, USA). Secondary antibodies were horseradish peroxidase (HRP)-conjugated anti-mouse IgG (Amersham Biosciences, Piscataway, NJ, USA); FITC-anti-mouse IgG and Texas Red-anti-rabbit (The Jackson Laboratory, Bar Harbor, ME, USA); and goat HRP-anti-mouse IgA, HRP-conjugated anti-IgA, anti-IgG or anti-IgM (Kirkegaard & Perry Laboratories, Gaithersburg, MD, USA).
Serum collection and screening for autoantibodies
Mice were euthanized by CO2 inhalation, and blood was drawn by intracardiac puncture or from the submandibular vein using Golden rod lancets (MediPoint Inc., Mineola, NY, USA). Blood was collected in serum separator tubes (BD Microtainer; BD Biosciences, Franklin Lakes, NJ, USA), stored at 4°C overnight and centrifuged at 14,000 rpm (5 min) to obtain serum. Sera were portioned into aliquots and stored at −20°C. Individual sera were screened for immunoreactivity to mouse liver total lysates using SDS-PAGE and immunoblotting with the Miniblotter System (Immunetics, Boston, MA, USA). Sera were incubated at 1:200 dilution in 5% fat-free milk (2 h) in PBS (pH 7.4), then incubated with HRP-anti-mouse IgG and detected using the Enhanced Chemiluminescence Plus kit (Perkin Elmer, Waltham, MA, USA). Sera were scored as positive if a signal was obtained in the 40–60 kDa range matching control sera.
Tissue collection and histology
Mouse tissues were fixed in 10% formalin for histologic analysis, or snap-frozen in liquid nitrogen for protein analysis. Fixed tissues were processed for paraffin embedding, sectioned, and stained with hematoxylin and eosin. Livers were scored in a blinded fashion (A.H.) for pathologic changes including inflammation, necrosis, vacuoles, giant cells, fat, and hemorrhage using a 4-point scale (0–4, none to maximum changes per parameter).
Immunofluorescence staining
Subconfluent NIH-3T3 and HT29 cells were grown on glass cover slips. Cells were fixed with 4% paraformaldehyde (in PBS, pH 7.4) then rinsed with 0.2% Nonidet P-40 (NP-40) and blocked (2.5% bovine serum albumin in PBS). K8−/− and K8+/+ mouse sera (1:30 dilutions) were used as primary antibodies, and nuclei were stained with Toto-3 (Invitrogen, Carlsbad, CA, USA). Liver tissue was fresh frozen in optimal cutting temperature compound, cryosectioned, fixed in −20°C acetone for 10 min, and stained as described above with anti-PMP70 antibodies and Draq5 (Cell Signaling, Danvers, MA, USA). Samples were analyzed by an LSM510 META confocal microscope (Carl Zeiss, Jena, Germany).
Protein solubility and trypsin digestion
Cells were lysed in 0.1% NP-40 buffer in PBS/5 mM EDTA, pH 7.5 (45 min, 4°C) and pelleted (14,000 rpm, 5 min), and the supernatant was collected (NP-40 soluble fraction) (31). The pellet was then solubilized in 0.1% Empigen/PBS, incubated, and pelleted as described previously to provide the Empigen-soluble and pellet (detergent-insoluble) fractions. The lysates were diluted in reducing Laemmli sample buffer and tested by blotting for reactivity to mouse sera. To test whether the autoantigen is a protein, the soluble fraction was incubated (37°C) with or without trypsin, followed by separation using 12% acrylamide gels. Antigen integrity was determined by blotting using the mouse sera.
Mitochondrial and peroxisome isolation and mass spectrometry
The liver mitochondrial fraction was isolated as described (32). Peroxisomes were isolated using a kit (Perox1, Sigma-Aldrich, as recommended by the supplier) from K8+/+ and AMA-positive K8−/− mice (8-mo-old males) that were placed on a water-only diet for 18 h prior to isolation. Mitochondrial homogenates were separated in 2 dimensions by isoelectric focusing (first dimension), then SDS-PAGE (second dimension). Identical gels were stained using Coomassie Brilliant Blue or transferred for immunoblotting using antibody-positive K8 sera. Antibody-reactive protein spots were excised from gels and/or the membrane, immersed with 100% acetonitrile, then digested overnight (37°C, 0.1 mg/ml trypsin) in 10 mM ammonium acetate containing 10% acetonitrile. The trypsinized proteins were identified using an Agilent 1100 LC mass spectrometry system (Agilent Technologies, Santa Clara, CA, USA). Mass spectrometry/mass spectrometry analysis was performed using the Spectrum Mill software (Agilent). A valid score (P < 0.05) is 13 for peptides and 20 for proteins, and a minimum of 2 valid peptides were counted for each protein.
Antigen identification approach
Immunofluorescence microscopy (as described above) was used to demonstrate that K8−/− or K18−/− autoantibody-positive mouse sera reacted with mitochondrial antigens. Serum autoantibody binding to the mitochondrial fraction was confirmed by immune blotting. Antigen confirmation was scored as positive if the purified test antigen bound selectively to autoantibody-positive mouse serum by immunoblotting of the test antibody with the purified antigen. Antigen verification was also carried out by testing whether preabsorption of the test AMA+ antibody with the purified protein decreased the reactivity of the autoantibody by immunoblotting. The purified antigens included glutamate dehydrogenase (GDH)1 (Sigma-Aldrich), mitochondrial 3-hydroxy-3-methylglutaryl coenzyme A synthase (HMGCS2; Genway, San Diego, CA, USA) and bovine catalase (Sigma-Aldrich). K8−/− serum was preabsorbed with the purified target proteins (7.5 µl serum + 1.38 µl protein at 1.45 µg/µl in 200 µl PBS-Tween). Samples were mixed for 30 min (22°C), then brought up to 1500 µl with PBS for immunoblotting of liver/cell lysates.
Statistics
The numbers are given as average ± sd, and statistical analysis was performed by Student’s t test.
RESULTS
Autoantibodies are readily detected in sera of aging male K8−/− and K18−/− mice
To test whether K8−/− mice develop autoantibodies, sera from K8−/− and control K8+/+ littermate mice were screened for autoantibodies by immunoblotting normal mouse liver lysates as potential antigen using 1:200 serum dilution. Among 10 pairs of mice, 60% of K8−/− mice but none of age- and sex-matched littermate K8+/+ mice displayed consistent reactivity toward a major antigen in the 40–60 kDa range (Fig. 1A). Screening of additional mice focusing on this molecular weight region confirmed the presence of a frequently occurring K8−/− autoantibody against a dominant autoantigen labeled as band C, and intermittent weaker reactivity toward 3 additional autoantigens labeled bands A, B, D (Fig. 1B). The autoantibodies were found in 57% of all random-selected and screened mice and in 81% of male mice 8 mo of age and older (Fig. 1C, D; Table 1), but rarely in young males or female K8−/− mice or in aging K8+/+ mice (Fig. 1D, Table 1). No differences in antigen reactivity were noted if the liver lysates used were from male or female mice, young or old mice, wild-type or K8−/− mice (not shown). Using secondary antibodies against mouse IgA, IgG, and IgM, the autoantibodies were determined to be IgG (not shown).
TABLE 1.
Genotype | Age (mo) | Total (n) | AMA positive |
Phenotype |
||
---|---|---|---|---|---|---|
% | n | Liver | Colon | |||
K8+/+ M + F | 2–18 | 51 | 6 | 3 | N | N |
K8+/− M + F | 8–18 | 16 | 6 | 1 | N | N/Ab |
K8−/− M + Fa | 2–7 | 16 | 0 | 0 | A | A |
M + F | 8–24 | 60 | 57 | 34 | A | A |
M | 8–24 | 27 | 81 | 22 | A | A |
F | 8–24 | 6 | 0 | 0 | A | A |
K18−/− M | 11–12 | 20 | 75 | 15 | A | N |
A, abnormal histology; N, normal histology. aSeventy-five percent males. bK8+/− colon appears normal but has a mild phenotype (19).
We then used sera from K18−/− mice, which manifest only a liver phenotype (14, 15), to dissect whether the autoantibodies are related to the liver or colon phenotype in the K8−/− mice. Similar to K8−/− mice, 11- to 12-mo-old K18−/− male mice develop autoantibodies that correspond to antigen C at a frequency of 75% (Table 1, Fig. 1D). Histologic scoring showed a trend (P = 0.18) but no significant difference in liver damage in autoantibody-positive compared with autoantibody-negative male K8−/− and K18−/− mice (Supplemental Table 1). In addition, there was no difference in liver histology between male and female K8−/− mice (not shown). No autoantibodies were detected in sera of mice that overexpress human wild-type K18 or a K18 R90C mutation (not shown). Similarly, no consistent autoantibodies in the same molecular weight range were observed in sera of mice subjected to 4 independent chronic liver injury models (high fat, porphyrinogenic toxin and 2 fibrosis injury models; see Materials and Methods), and only few occasional mice manifested a weak signal (Supplemental Fig. 1). Even if mouse models may have lower titers than the human disease (33), the serum dilution of 1:200 we used gave a robust signal in positive mice. Taken together, K8−/− and K18−/− male mice produce upon aging serum IgG-type autoantibodies that recognize 40–60 kDa autoantigens.
The main autoantigen is a ubiquitous and soluble protein
To further characterize the autoantigens, representative C-antigen-reactive-sera from K8−/− mice and sera from K8+/+ mice were used to detect antigens in various tissues and cell lines. Sera from K8−/− but not K8+/+ mice recognized antigens in human and mouse cell lines of fibroblast, liver, colon, and exocrine pancreatic origin (Fig. 1E), where the only K8−/− mouse antigen signals detected (Fig. 1E) matched in molecular weight those of the mouse tissue in the 50 kDa range (not shown). A similar antigen was also detected in lysates of small intestine, colon, kidney, lung, heart, spleen, and brain (Supplemental Fig. 1).
To analyze the properties of the autoantigens, NIH-3T3 cell lysates were fractionated into detergent soluble (NP-40, Empigen) and insoluble fractions. The major C autoantigen is found primarily in the NP-40 fraction, in contrast to the IF protein vimentin, which is soluble primarily in the stronger detergent Empigen (Fig. 1F). The antigen recognized by K8−/− sera is a protein, because it is readily digested by trypsin in NIH-3T3 cell lysates after 5 min at 37°C (Fig. 1G). The K8−/− autoantigen is thus a ubiquitous protein that is readily solubilized by NP-40.
The K8−/− autoantigens are mitochondrial proteins
To determine the subcellular localization of the antigens recognized by the K8−/− autoantibodies, an immunofluorescence staining was performed on NIH-3T3 cells. Sera positive for the 40–60 kDa proteins manifested cytoplasmic reticular and perinuclear staining patterns (Fig. 2B, D) not seen in antibody-negative K8−/− sera (Fig. 2F) or K8+/+ sera (Fig. 2A, C, E). Similar results were obtained using HT29 cells (not shown). Costaining using autoantibody-positive K8−/− sera with markers for Golgi and mitochondria revealed primarily a mitochondrial distribution for the autoantigen (Fig. 3A). Sera from a few K8−/− and K18−/− mice colocalized with ends of F-actin stress fibers and vinculin at filopodia (not shown). Occasional sera from aging mice carried autoantibodies to unidentified proteins (see Fig. 1), which were not further analyzed.
To biochemically identify the autoantigens, mouse liver mitochondria were purified by subcellular fractionation (Fig. 3B) and separated using 2-dimensional electrophoresis. The mitochondrial-enriched proteins were visualized by Coomassie Brilliant Blue staining (Fig. 4A) and analyzed by immunoblotting using K8−/− sera (Fig. 4B) on parallel gels. The Coomassie Brilliant Blue-stained dots that colocalized with the immune-reactive spots were identified using mass spectrometry as GDH1 for antigen B and a mixture of mitochondrial HMG-CoA synthase (HMGCS2), catalase, and aldehyde dehydrogenase (ALDH) E2 for antigen C; the less abundant antigen A was identified as epoxide hydrolase 2 (Table 2).
TABLE 2.
Spot | MW (kDa) | No. of peptides | Score | AA coverage (%) | Protein |
---|---|---|---|---|---|
A | 62 | 5 | 94 | 13 | Epoxide hydrolase 2 |
B1a | 61 | 10 | 61 | 22 | GDH1 |
B1b | 12 | 185 | 27 | ||
B1c | 9 | 131 | 18 | ||
C1a | 57 | 4 | 61 | 7 | HMGCS2 |
B1b | 1 | 16 | 1 | ||
C1a | 57 | 2 | 61 | 5 | Catalase |
B1b | 1 | 31 | 2 | ||
C2 | 53 | 4 | 53 | 7 | ALDH E2 |
AA, amino acid. Spot refers to the 2D protein spots identified and shown in Fig. 4A and B.
Validation of GDH1 and HMGCS2 as primary autoantigens
To validate the identified antigens, the commercially purified GDH1 and HMGCS2 proteins were analyzed by 2 approaches: 1) directly by immunoblotting purified putative antigens with K8−/− mouse sera to determine if the autoantibody identifies these proteins as antigens, and 2) preabsorption of sera with purified GDH1 and HMGCS2 autoantigens. Autoantibodies against antigen B but not antigen C detected purified GDH1 (Fig. 4C). Preabsorption of antigen B sera using purified GDH1 diminished but did not completely remove the Western blot signal for GHD1, supporting that the B antigen corresponds in part to GDH1 (Fig. 4D). Likewise, bacterially expressed HMGCS2 loaded onto gels and probed with mouse serum shows that the K8−/− C sera reacts stronger with HMGCS2, compared with K8+/+ serum (Fig. 4E). Preabsorption of 2 different K8−/− sera with HMGCS2 and probing of filters with K8−/− serum shows a decreased signal when the serum was preabsorbed (Fig. 4F). For catalase, also a minor decrease in C antigen signal in liver lysates was noted after incubation of the mouse serum with purified bovine catalase (not shown).
DISCUSSION
IF mutations cause or predispose to multiple tissue-specific human diseases, and these diseases parallel the tissue-specific expression of IFs and are phenocopied in IF-related genetic mouse models (3, 34). Some of the diseases have an autoimmune component; however, it is unknown whether the mouse models mimic the human disease in terms of presence of autoantibodies as has been described in other mouse models of autoimmune disease (26, 35). Our findings show that aging K8−/− and K18−/− male mice produce AMA at reasonably high titers. The liver is the likely source of autoantigens because K8−/− and K18−/− knockout mice both have a similar major phenotype in the liver (15), although K8−/− but not K18−/− mice also develop spontaneous colitis (13, 19–21). The liver phenotype, which has been extensively studied in K8−/− mice, includes predisposition to hepatotoxic injury (36–38) and apoptosis (16, 17) and profound hepatocyte fragility upon liver perfusion (39). Both genotypes have patchy loss of hepatocytes with replacement by multinucleated giant cells (15). K18−/− but not K8−/− mice develop spontaneous Mallory-Denk bodies (MDBs) with old age (14), thereby suggesting that the MDBs are not related to the AMA, albeit male mice are more susceptible to MDB formation (40). In the K8−/− and K18−/− livers, hepatocyte rather than biliary damage is likely the source of antigen exposure. The reason for this assessment is that there is no major pathology in the biliary system (not shown) (13) and bile ducts express primarily K19 and K7, in contrast to adult hepatocytes, which express only K8 and K18 (41), with the latter being more susceptible to injury in the absence of K8.
K8−/− hepatocyte mitochondria are smaller and irregularly distributed and have decreased ATP and cytochrome c levels (42), with altered hepatic glucose/glycogen metabolism (43). Notably, proteomic analysis of K8−/− hepatocytes (42) showed that 13 mitochondrial proteins had altered charged isoforms, including 3 of the autoantigens (GDH, ALDH, HMGCS2) we identified herein. It is likely that the keratin-dependent chronic mitochondrial stress and hepatocyte fragility lead to exposure of inner mitochondrial proteins to the immune system with consequent production of AMA, which highlights hepatocyte mitochondria as likely to be central in this phenotype. In PBC, where PBC-specific AMA is an important hallmark of disease and PDC-E2 the major antigen, the affected cholangiocyte apoptotic bodies are believed to be the antigen-presenting entity (26). The male preponderance of AMA in K8−/−/K18−/− mice is unlike PBC, which is more frequent in females (44), but resembles PSC, which has a 2:1 male:female ratio and is typically associated with antineutrophil cytoplasmic antibodies rather than AMA (45). It is likely that sex-dependent human autoimmune diseases are related to hormonal causes, fetal microchimerism, or X-chromosome changes (26). Given that catalase is one of the autoantigens we observed, peroxisomal damage is also a potential source of the autoantigens. Notably, we did not observe an obvious alteration in the organization of peroxisomes or loss of the peroxisomal membrane protein PMP70 (based on immunofluorescence staining and immunoblotting, respectively; not shown). However, our findings cannot completely exclude the possibility of a peroxisomal defect that could contribute to the generation of the autoantibodies we observed.
The K8−/−/K18−/− and the K18 R90C mice have either absent or disrupted cytoskeletal keratin networks, respectively. However, AMA were not found in K18 R90C mice, which raises the possibility that the presence of some keratins, albeit disorganized, is protective. However, another contributing factor may be the altered thymic epithelium in K8−/− mice (46), although this has not been examined in K18−/− or K18 R90C mice and the immunologic consequences of such disruption of the thymic epithelium are unknown. In addition, chronic liver injury per se (up to 8 wk, Supplemental Fig. 1) does not appear to be the culprit in the formation of the autoantibodies, although we cannot exclude the possibility that longer-term chronic injury (which we did not test) may potentially result in autoantibody formation independent of keratin absence or mutation. The implication of our findings is that the defect caused by keratin absence from birth, together with the age effect, promotes antibody formation but in the context of male gender.
The K8−/− mouse autoantigens HMGCS2, catalase, and ALDH E2 are involved in energy metabolism and oxidative stress. HMGCS2, a rate-limiting ketogenic pathway enzyme, is important for energy production under ketogenic conditions such as starvation (47) and was recently found to be down-regulated in the colon of K8−/− mice (48). Whether such circulating autoantibodies would have pathophysiologic consequences in another organ is not known. The K8−/− mice have colitis, which starts within the first 2 wk after birth (19) indicating that the colitis phenotype is not caused by autoantibody formation. Notably, anti-catalase autoantibodies were reported in 60% of a PSC patient cohort (49) and in rat models of acute fibrosing cholangitis (50). The antioxidant catalase was also found as one of the anti-soluble liver antigens in autoimmune hepatitis type-1 (51). ALDH E2 is important in oxidative stress and part of a large family of NAD(P)+-dependent dehydrogenases (52). Anti-ALDH antibodies are found in cases of unexplained infertility (53) and cancer (54), and ALDH 4A1 levels are significantly changed in K8−/− hepatocyte mitochondria (42). GDH1, a mitochondrial matrix protein with roles in glutamate and energy metabolism, was also identified among the autoantigens. GDH mutations leads to the hyperinsulinism/hyperammonemia syndrome (55), and GDH is up-regulated in liver disease (56). The remaining autoantigen we identified, epoxide hydrolase 2, is a cytoplasmic protein that is important in detoxification (57). Taken together, our findings raise the possibility that AMA may also be found in patients who harbor keratin variants that predispose to liver disease progression or in association with other IF-associated diseases.
Acknowledgments
The authors thank Hélène Baribault and Thomas Magin for providing the K8−/− and K18−/− mice, respectively, and P. J. Utz for fruitful discussions. Che-Hong Chen is acknowledged for assistance with the 2D-PAGE. The authors also thank Matilda Holm, Neeraj Prabhakar, Jolanta Lundgren, and Helena Saarento for technical assistance. This work was supported by U.S. National Institutes of Health Grants DK47918 (to M.B.O.), K08-DK069385 (to A.H.), DK56339 (Stanford University), and DK34933 (University of Michigan); Academy of Finland #140759/126161 and 266582, Sigrid Juselius Foundation, Liv och Hälsa Foundation, EU FP7 IRG, and ÅAU Center of Excellence (D.M.T.); Turku Doctoral Programme for Biomedical Sciences (J.O.M.); Makarna Agneta och Carl-Erik Olin Foundation (J.H.N.); and the U.S. Department of Veterans Affairs (M.B.O.). The authors declare no conflicts of interest.
Glossary
- ALDH
aldehyde dehydrogenase
- AMA
anti-mitochondrial autoantibodies
- GDH
glutamate dehydrogenase
- HMGCS2
mitochondrial 3-hydroxy-3-methylglutaryl coenzyme A synthase
- HRP
horseradish peroxidase
- IBD
inflammatory bowel disease
- IF
intermediate filament
- K8
keratin 8
- K18
keratin 18
- K8+/+
wild-type nontransgenic
- K8−/−
K8-null
- K18−/−
K18-null
- MDB
Mallory-Denk bodies
- NP-40
Nonidet P-40
- PBC
primary biliary cirrhosis
- PSC
primary sclerosing cholangitis
Footnotes
This article includes supplemental data. Please visit http://www.fasebj.org to obtain this information.
REFERENCES
- 1.Schweizer J., Bowden P. E., Coulombe P. A., Langbein L., Lane E. B., Magin T. M., Maltais L., Omary M. B., Parry D. A., Rogers M. A., Wright M. W. (2006) New consensus nomenclature for mammalian keratins. J. Cell Biol. 174, 169–174 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Szeverenyi I., Cassidy A. J., Chung C. W., Lee B. T., Common J. E., Ogg S. C., Chen H., Sim S. Y., Goh W. L., Ng K. W., Simpson J. A., Chee L. L., Eng G. H., Li B., Lunny D. P., Chuon D., Venkatesh A., Khoo K. H., McLean W. H., Lim Y. P., Lane E. B. (2008) The Human Intermediate Filament Database: comprehensive information on a gene family involved in many human diseases. Hum. Mutat. 29, 351–360 [DOI] [PubMed] [Google Scholar]
- 3.Omary M. B., Ku N. O., Strnad P., Hanada S. (2009) Toward unraveling the complexity of simple epithelial keratins in human disease. J. Clin. Invest. 119, 1794–1805 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Toivola D. M., Strnad P., Habtezion A., Omary M. B. (2010) Intermediate filaments take the heat as stress proteins. Trends Cell Biol. 20, 79–91 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Pan X., Hobbs R. P., Coulombe P. A. (2013) The expanding significance of keratin intermediate filaments in normal and diseased epithelia. Curr. Opin. Cell Biol. 25, 47–56 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Omary M. B., Coulombe P. A., McLean W. H. (2004) Intermediate filament proteins and their associated diseases. N. Engl. J. Med. 351, 2087–2100 [DOI] [PubMed] [Google Scholar]
- 7.Omary M. B. (2009) “IF-pathies”: a broad spectrum of intermediate filament-associated diseases. J. Clin. Invest. 119, 1756–1762 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Zhong B., Strnad P., Selmi C., Invernizzi P., Tao G. Z., Caleffi A., Chen M., Bianchi I., Podda M., Pietrangelo A., Gershwin M. E., Omary M. B. (2009) Keratin variants are overrepresented in primary biliary cirrhosis and associate with disease severity. Hepatology 50, 546–554 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Strnad P., Lienau T. C., Tao G. Z., Lazzeroni L. C., Stickel F., Schuppan D., Omary M. B. (2006) Keratin variants associate with progression of fibrosis during chronic hepatitis C infection. Hepatology 43, 1354–1363 [DOI] [PubMed] [Google Scholar]
- 10.Strnad P., Zhou Q., Hanada S., Lazzeroni L. C., Zhong B. H., So P., Davern T. J., Lee W. M.; Acute Liver Failure Study Group, Omary M. B. (2010) Keratin variants predispose to acute liver failure and adverse outcome: race and ethnic associations. Gastroenterology 139, 828–835, 835.e1–835.e13 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Tao G. Z., Strnad P., Zhou Q., Kamal A., Zhang L., Madani N. D., Kugathasan S., Brant S. R., Cho J. H., Omary M. B., Duerr R. H. (2007) Analysis of keratin polypeptides 8 and 19 variants in inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 5, 857–864 [DOI] [PubMed] [Google Scholar]
- 12.Strnad P., Paschke S., Jang K. H., Ku N. O. (2012) Keratins: markers and modulators of liver disease. Curr. Opin. Gastroenterol. 28, 209–216 [DOI] [PubMed] [Google Scholar]
- 13.Baribault H., Penner J., Iozzo R. V., Wilson-Heiner M. (1994) Colorectal hyperplasia and inflammation in keratin 8-deficient FVB/N mice. Genes Dev. 8, 2964–2973 [DOI] [PubMed] [Google Scholar]
- 14.Magin T. M., Schröder R., Leitgeb S., Wanninger F., Zatloukal K., Grund C., Melton D. W. (1998) Lessons from keratin 18 knockout mice: formation of novel keratin filaments, secondary loss of keratin 7 and accumulation of liver-specific keratin 8-positive aggregates. J. Cell Biol. 140, 1441–1451 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Toivola D. M., Nieminen M. I., Hesse M., He T., Baribault H., Magin T. M., Omary M. B., Eriksson J. E. (2001) Disturbances in hepatic cell-cycle regulation in mice with assembly-deficient keratins 8/18. Hepatology 34, 1174–1183 [DOI] [PubMed] [Google Scholar]
- 16.Gilbert S., Loranger A., Daigle N., Marceau N. (2001) Simple epithelium keratins 8 and 18 provide resistance to Fas-mediated apoptosis. The protection occurs through a receptor-targeting modulation. J. Cell Biol. 154, 763–773 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Leifeld L., Kothe S., Söhl G., Hesse M., Sauerbruch T., Magin T. M., Spengler U. (2009) Keratin 18 provides resistance to Fas-mediated liver failure in mice. Eur. J. Clin. Invest. 39, 481–488 [DOI] [PubMed] [Google Scholar]
- 18.Ku N. O., Omary M. B. (2000) Keratins turn over by ubiquitination in a phosphorylation-modulated fashion. J. Cell Biol. 149, 547–552 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Toivola D. M., Krishnan S., Binder H. J., Singh S. K., Omary M. B. (2004) Keratins modulate colonocyte electrolyte transport via protein mistargeting. J. Cell Biol. 164, 911–921 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Habtezion A., Toivola D. M., Butcher E. C., Omary M. B. (2005) Keratin-8-deficient mice develop chronic spontaneous Th2 colitis amenable to antibiotic treatment. J. Cell Sci. 118, 1971–1980 [DOI] [PubMed] [Google Scholar]
- 21.Habtezion A., Toivola D. M., Asghar M. N., Kronmal G. S., Brooks J. D., Butcher E. C., Omary M. B. (2011) Absence of keratin 8 confers a paradoxical microflora-dependent resistance to apoptosis in the colon. Proc. Natl. Acad. Sci. USA 108, 1445–1450 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Mombaerts P., Mizoguchi E., Grusby M. J., Glimcher L. H., Bhan A. K., Tonegawa S. (1993) Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell 75, 274–282 [DOI] [PubMed] [Google Scholar]
- 23.Kühn R., Löhler J., Rennick D., Rajewsky K., Müller W. (1993) Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75, 263–274 [DOI] [PubMed] [Google Scholar]
- 24.Herszényi L., Tulassay Z. (2012) The role of autoantibodies in inflammatory bowel disease. Dig. Dis. 30, 201–207 [DOI] [PubMed] [Google Scholar]
- 25.Gossard A. A., Lindor K. D. (2012) Autoimmune hepatitis: a review. J. Gastroenterol. 47, 498–503 [DOI] [PubMed] [Google Scholar]
- 26.Hirschfield G. M., Gershwin M. E. (2013) The immunobiology and pathophysiology of primary biliary cirrhosis. Annu. Rev. Pathol. 8, 303–330 [DOI] [PubMed] [Google Scholar]
- 27.Ku N. O., Soetikno R. M., Omary M. B. (2003) Keratin mutation in transgenic mice predisposes to Fas but not TNF-induced apoptosis and massive liver injury. Hepatology 37, 1006–1014 [DOI] [PubMed] [Google Scholar]
- 28.Kohli R., Kirby M., Xanthakos S. A., Softic S., Feldstein A. E., Saxena V., Tang P. H., Miles L., Miles M. V., Balistreri W. F., Woods S. C., Seeley R. J. (2010) High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 52, 934–944 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Hanada S., Strnad P., Brunt E. M., Omary M. B. (2008) The genetic background modulates susceptibility to mouse liver Mallory-Denk body formation and liver injury. Hepatology 48, 943–952 [DOI] [PubMed] [Google Scholar]
- 30.Strnad P., Tao G. Z., Zhou Q., Harada M., Toivola D. M., Brunt E. M., Omary M. B. (2008) Keratin mutation predisposes to mouse liver fibrosis and unmasks differential effects of the carbon tetrachloride and thioacetamide models. Gastroenterology 134, 1169–1179 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Ku N. O., Toivola D. M., Zhou Q., Tao G. Z., Zhong B., Omary M. B. (2004) Studying simple epithelial keratins in cells and tissues. Methods Cell Biol. 78, 489–517 [DOI] [PubMed] [Google Scholar]
- 32.Nonn L., Williams R. R., Erickson R. P., Powis G. (2003) The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice. Mol. Cell. Biol. 23, 916–922 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Hohenester S., Beuers U., Medina J. F., Elferink R. P. (2013) Antimitochondrial antibodies may be insufficiently specific to define primary biliary cirrhosis-like disease in mouse models. Hepatology 58, 828–830 [DOI] [PubMed] [Google Scholar]
- 34.Fuchs E., Cleveland D. W. (1998) A structural scaffolding of intermediate filaments in health and disease. Science 279, 514–519 [DOI] [PubMed] [Google Scholar]
- 35.Chiorini J. A., Cihakova D., Ouellette C. E., Caturegli P. (2009) Sjögren syndrome: advances in the pathogenesis from animal models. J. Autoimmun. 33, 190–196 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Toivola D. M., Omary M. B., Ku N. O., Peltola O., Baribault H., Eriksson J. E. (1998) Protein phosphatase inhibition in normal and keratin 8/18 assembly-incompetent mouse strains supports a functional role of keratin intermediate filaments in preserving hepatocyte integrity. Hepatology 28, 116–128 [DOI] [PubMed] [Google Scholar]
- 37.Caulin C., Ware C. F., Magin T. M., Oshima R. G. (2000) Keratin-dependent, epithelial resistance to tumor necrosis factor-induced apoptosis. J. Cell Biol. 149, 17–22 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Fickert P., Fuchsbichler A., Wagner M., Silbert D., Zatloukal K., Denk H., Trauner M. (2009) The role of the hepatocyte cytokeratin network in bile formation and resistance to bile acid challenge and cholestasis in mice. Hepatology 50, 893–899 [DOI] [PubMed] [Google Scholar]
- 39.Loranger A., Duclos S., Grenier A., Price J., Wilson-Heiner M., Baribault H., Marceau N. (1997) Simple epithelium keratins are required for maintenance of hepatocyte integrity. Am. J. Pathol. 151, 1673–1683 [PMC free article] [PubMed] [Google Scholar]
- 40.Hanada S., Snider N. T., Brunt E. M., Hollenberg P. F., Omary M. B. (2010) Gender dimorphic formation of mouse Mallory-Denk bodies and the role of xenobiotic metabolism and oxidative stress. Gastroenterology 138, 1607–1617 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Ku N. O., Zhou X., Toivola D. M., Omary M. B. (1999) The cytoskeleton of digestive epithelia in health and disease. Am. J. Physiol. 277, G1108–G1137 [DOI] [PubMed] [Google Scholar]
- 42.Tao G. Z., Looi K. S., Toivola D. M., Strnad P., Zhou Q., Liao J., Wei Y., Habtezion A., Omary M. B. (2009) Keratins modulate the shape and function of hepatocyte mitochondria: a mechanism for protection from apoptosis. J. Cell Sci. 122, 3851–3855 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Mathew J., Loranger A., Gilbert S., Faure R., Marceau N. (2013) Keratin 8/18 regulation of glucose metabolism in normal versus cancerous hepatic cells through differential modulation of hexokinase status and insulin signaling. Exp. Cell Res. 319, 474–486 [DOI] [PubMed] [Google Scholar]
- 44.Tiniakou E., Costenbader K. H., Kriegel M. A. (2013) Sex-specific environmental influences on the development of autoimmune diseases. Clin. Immunol. 149, 182–191 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Fallatah H. I., Akbar H. O. (2011) Autoimmune liver disease—are there spectra that we do not know? Comp. Hepatol. 10, 9 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Odaka C., Loranger A., Takizawa K., Ouellet M., Tremblay M. J., Murata S., Inoko A., Inagaki M., Marceau N. (2013) Keratin 8 is required for the maintenance of architectural structure in thymus epithelium. PLoS One 8, e75101 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Hegardt F. G. (1999) Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase: a control enzyme in ketogenesis. Biochem. J. 338, 569–582 [PMC free article] [PubMed] [Google Scholar]
- 48.Helenius T. O., Misiorek J. O., Nyström J. H., Fortelius L. E., Habtezion A., Liao J., Asghar M. N., Zhang H., Azhar S., Omary M. B., Toivola D. M. (2015) Keratin 8 absence down-regulates colonocyte HMGCS2 and modulates colonic ketogenesis and energy metabolism. Mol. Biol. Cell 26, 2298–2310 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Orth T., Kellner R., Diekmann O., Faust J., Meyer zum Büschenfelde K. H., Mayet W. J. (1998) Identification and characterization of autoantibodies against catalase and alpha-enolase in patients with primary sclerosing cholangitis. Clin. Exp. Immunol. 112, 507–515 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Orth T., Neurath M., Schirmacher P., Galle P. R., Mayet W. J. (2000) A novel rat model of chronic fibrosing cholangitis induced by local administration of a hapten reagent into the dilated bile duct is associated with increased TNF-alpha production and autoantibodies. J. Hepatol. 33, 862–872 [DOI] [PubMed] [Google Scholar]
- 51.Ballot E., Bruneel A., Labas V., Johanet C. (2003) Identification of rat targets of anti-soluble liver antigen autoantibodies by serologic proteome analysis. Clin. Chem. 49, 634–643 [DOI] [PubMed] [Google Scholar]
- 52.Yoshida A., Rzhetsky A., Hsu L. C., Chang C. (1998) Human aldehyde dehydrogenase gene family. Eur. J. Biochem. 251, 549–557 [DOI] [PubMed] [Google Scholar]
- 53.Edassery S. L., Shatavi S. V., Kunkel J. P., Hauer C., Brucker C., Penumatsa K., Yu Y., Dias J. A., Luborsky J. L. (2010) Autoantigens in ovarian autoimmunity associated with unexplained infertility and premature ovarian failure. Fertil. Steril. 94, 2636–2641 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Nakanishi T., Takeuchi T., Ueda K., Murao H., Shimizu A. (2006) Detection of eight antibodies in cancer patients’ sera against proteins derived from the adenocarcinoma A549 cell line using proteomics-based analysis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 838, 15–20 [DOI] [PubMed] [Google Scholar]
- 55.Karaca M., Frigerio F., Maechler P. (2011) From pancreatic islets to central nervous system, the importance of glutamate dehydrogenase for the control of energy homeostasis. Neurochem. Int. 59, 510–517 [DOI] [PubMed] [Google Scholar]
- 56.Ozer J., Ratner M., Shaw M., Bailey W., Schomaker S. (2008) The current state of serum biomarkers of hepatotoxicity. Toxicology 245, 194–205 [DOI] [PubMed] [Google Scholar]
- 57.Decker M., Arand M., Cronin A. (2009) Mammalian epoxide hydrolases in xenobiotic metabolism and signalling. Arch. Toxicol. 83, 297–318 [DOI] [PubMed] [Google Scholar]